Axsome Therapeutics collaborates with Duke University nicotine addiction research center
Axsome Therapeutics announced it has entered into a research collaboration with Duke University to evaluate AXS-05 in a Phase 2 clinical trial in smokers attempting to quit. AXS-05 is a novel, oral, fixed-dose combination of dextromethorphan and bupropion. December 14, 2017